Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) shares were down 1.2% during mid-day trading on Thursday . The stock traded as low as $4.03 and last traded at $4.04. Approximately 170,644 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 261,100 shares. The stock had previously closed at $4.09.
Aadi Bioscience Price Performance
The firm has a market capitalization of $99.78 million, a P/E ratio of -1.77 and a beta of 0.68. The stock’s fifty day simple moving average is $4.29 and its 200 day simple moving average is $4.11.
About Aadi Bioscience
Aadi Bioscience, Inc is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers. Its work has centered on treatments that target molecular pathways involved in tumor growth, with an emphasis on rare and underserved oncology indications.
The company’s principal product is FYARRO (sirolimus protein-bound particles for injectable suspension), also known as nab-sirolimus. The U.S. Food and Drug Administration approved FYARRO in 2021 for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, a rare form of cancer.
Further Reading
- Five stocks we like better than Aadi Bioscience
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
